Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nucleolar protein 6 (NOL6) is a highly conserved nucleolar RNA-associated protein coded by the NOL6 gene and involved primarily in ribosome biogenesis. It interacts with pre-rRNA primary transcripts and is essential for the formation and function of ribosomes in the nucleolus[2][3][7]. NOL6 is RNA-dependent for its nucleolar localization and is found in at least two isoforms due to alternative splicing[3][7]. Emerging evidence identifies NOL6 as a cancer-associated gene, functioning as an oncogenic driver that promotes cell proliferation and migration and inhibits apoptosis, notably in liver, prostate, and endometrial cancers, partly via the regulation of transcription factors such as TWIST1[2][5][6]. NOL6 is being explored as a potential prognostic biomarker and therapeutic target in oncology[2][5].
microRNA-based inhibition (e.g., miR-590-3p suppresses NOL6, resulting in decreased cancer cell proliferation and increased apoptosis)[5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nucleolar protein 6 (NOL6).